Angiotensin II type 2 receptor agonists: where should they be applied?

Expert Opinion on Investigational Drugs
Koen VerdonkJoep H M van Esch

Abstract

Angiotensin II, the active endproduct of the renin-angiotensin system (RAS), exerts its effects via angiotensin II type 1 and type 2 (AT(1), AT(2)) receptors. AT(1) receptors mediate all well-known effects of angiotensin II, ranging from vasoconstriction to tissue remodeling. Thus, to treat cardiovascular disease, RAS blockade aims at preventing angiotensin II-AT(1) receptor interaction. Yet RAS blockade is often accompanied by rises in angiotensin II, which may exert beneficial effects via AT(2) receptors. This review summarizes our current knowledge on AT(2) receptors, describing their location, function(s), endogenous agonist(s) and intracellular signaling cascades. It discusses the beneficial effects obtained with C21, a recently developed AT(2) receptor agonist. Important questions that are addressed are do these receptors truly antagonize AT(1) receptor-mediated effects? What about their role in the diseased state and their heterodimerization with other receptors? The general view that AT(2) receptors exclusively exert beneficial effects has been challenged, and in pathological models, their function sometimes mimics that of AT(1) receptors, for example, inducing vasoconstriction and cardiac hypertrophy. Yet given its upr...Continue Reading

References

Dec 1, 1992·Circulation Research·L A SechiM Schambelan
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M A MillanK J Catt
Sep 1, 1991·The Journal of Clinical Investigation·E F GradyJ E Kalinyak
Nov 30, 1989·Biochemical and Biophysical Research Communications·A T ChiuA L Johnson
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·M NakajimaV J Dzau
Apr 1, 1995·Kidney International·S ShanmugamC M Llorens-Cortes
Jul 1, 1994·Hypertension·A H DanserM A Schalekamp
Oct 1, 1993·Hypertension·D J CampbellA M Duncan
Dec 22, 1995·The Journal of Biological Chemistry·M Belfort, P S Perlman
Jun 21, 1996·The Journal of Biological Chemistry·J Zhang, R E Pratt
Aug 30, 1996·Molecular and Cellular Endocrinology·S MeffertT Unger
Jul 15, 1997·The Journal of Clinical Investigation·H M Siragy, R M Carey
Aug 1, 1997·Journal of Molecular and Cellular Cardiology·C A van KesterenA H Danser
Jan 4, 1998·Kidney International·R Ardaillou, D Chansel
May 7, 1998·European Journal of Pharmacology·R BouleyE Escher
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·N O DulinJ G Douglas
Jan 15, 1999·Endocrine Research·M HoriuchiV J Dzau
Sep 9, 1999·European Journal of Pharmacology·J R McMullenJ Wu
Oct 8, 1999·The Journal of Clinical Investigation·Y TsutsumiT Iwasaka
Jan 5, 2000·Kidney International·V GrossF C Luft

❮ Previous
Next ❯

Citations

Dec 12, 2012·Current Hypertension Reports·Claudia A McCarthyEmma S Jones
Jan 15, 2014·Current Hypertension Reports·Pawel NamsolleckThomas Unger
Nov 21, 2012·Nature Reviews. Nephrology·Bruno Sevá PessôaA H Jan Danser
Jan 29, 2013·Clinical and Experimental Pharmacology & Physiology·Ross G DouglasEdward D Sturrock
Nov 15, 2012·American Journal of Physiology. Endocrinology and Metabolism·Michaël ShumNicole Gallo-Payet
Jan 16, 2013·International Journal of Hypertension·Marie-Odile Guimond, Nicole Gallo-Payet
Oct 16, 2014·Expert Opinion on Therapeutic Targets·Maree T Smith, Arjun Muralidharan
Aug 21, 2013·Expert Opinion on Therapeutic Targets·Nelly Blaes, Jean-Pierre Girolami
Apr 24, 2012·Expert Opinion on Investigational Drugs·Ulrike Muscha Steckelings, Thomas Unger
Jun 21, 2014·Cell·A H Jan Danser, Praveen Anand
Aug 5, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francisco WestermeierSergio Lavandero
Mar 15, 2015·Circulation Research·Luuk Te RietA H Jan Danser
Jun 22, 2014·American Journal of Physiology. Lung Cellular and Molecular Physiology·Gerry T M WagenaarFrans J Walther
Nov 7, 2013·Journal of Cardiovascular Pharmacology·Ying LiHong Yuan
Jul 3, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Gerry T M WagenaarFrans J Walther
Apr 30, 2017·Experimental and Therapeutic Medicine·Bingbing PanQulian Guo
Jun 6, 2018·Frontiers in Physiology·Arthur D MoesEwout J Hoorn
Jan 23, 2020·Journal of Clinical Medicine·Amalie L PovlsenMarcus Krüger
Sep 10, 2020·British Journal of Pharmacology·Daolai ZhangZhigang Xu
Oct 22, 2016·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Jay S MishraSathish Kumar
Nov 30, 2021·Journal of Cardiovascular Pharmacology·Edwyn O Cruz-LópezA H Jan Danser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Aneurysm

Aneurysms are outward distensions or bulges that occurs in a weakened wall of blood vessels. Discover the latest research on aneurysms here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Related Papers

Current Opinion in Pharmacology
U Muscha SteckelingsThomas Unger
Current Opinion in Nephrology and Hypertension
Carmine SavoiaMassimo Volpe
Expert Opinion on Investigational Drugs
U Muscha Steckelings, Thomas Unger
© 2022 Meta ULC. All rights reserved